Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for reversal of neuromuscular blockade in lung cancer surgery
ChiCTR2000039572Phase 4Recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jan 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Sugammadex and neostigmine in bronchial carcinoma and postoperative respiratory complications (PRC) (2 arms), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoints: Muscle relaxation recovery time and Postoperative pulmonary complications. Started Jan 2021; status: recruiting.
02
Drugs
Sugammadexneostigmine
03
Conditions
bronchial carcinomapostoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2000039572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039572.